Welcome to our dedicated page for Nasus Pharma Ltd. news (Ticker: NSRX), a resource for investors and traders seeking the latest updates and insights on Nasus Pharma Ltd. stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Nasus Pharma Ltd.'s stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Nasus Pharma Ltd.'s position in the market.
Nasus Pharma (NYSE: NSRX) announced the appointment of Eyal Rubin as Executive Vice President and Chief Financial Officer effective Nov 20, 2025. Rubin brings more than two decades of financial leadership in biotechnology and pharma and will lead corporate finance, financial planning, capital strategy, and investor relations as Nasus advances its intranasal therapeutic pipeline toward clinical and commercial milestones.
Rubin previously served as CFO at Protalix BioTherapeutics and BrainStorm Cell Therapeutics and held treasury leadership at Teva. He holds a BA in Business Management and an MBA in Accounting and Finance, both summa cum laude. Company leaders said Rubin’s capital markets experience will support Nasus’s growth phase.
Nasus Pharma (NYSE: NSRX) received a No-Objection Letter from Health Canada on Nov 6, 2025, clearing the company to proceed with a planned Phase 2 clinical study of NS002, an investigational intranasal epinephrine powder for anaphylaxis.
The authorization confirms acceptability of the proposed trial design, provided safety data, and manufacturing information, and enables Nasus to advance toward initiating the Phase 2 study using its proprietary Nasax technology.
Nasus Pharma (NYSE: NSRX) announced on October 8, 2025 expanded agreements with Aptar France and AptarGroup to support development and planned commercialization of NS002, an intranasal powder epinephrine candidate.
The collaboration secures a commercially proven Unit Dose System technology, access to Aptar's manufacturing, supply‑chain and technical expertise, and establishes a framework to support regulatory submissions to the FDA and EMA, aiming to accelerate NS002's path to market and reduce development risk.
Nasus Pharma (NYSE:NSRX), a clinical-stage pharmaceutical company specializing in intranasal emergency medical treatments, has announced its participation in the H.C. Wainwright 27th Annual Global Investment Conference. The virtual presentation will be delivered by CEO Dan Teleman on September 5, 2025, from 7:00-7:30 AM ET.
The company will also be available for one-on-one meetings with investors during the conference, which can be arranged through H.C. Wainwright representatives.
Nasus Pharma (NYSE:NSRX), a clinical-stage pharmaceutical company, celebrated its NYSE American listing with a Closing Bell ceremony on August 25, 2025. The company specializes in developing innovative intranasal products for emergency medical conditions.
Led by CEO Dan Teleman, Nasus Pharma is advancing its proprietary intranasal powder technology platform, focusing on treatments for severe allergic reactions and anaphylaxis. The company aims to provide needle-free, fast-acting alternatives to traditional emergency medications, particularly targeting families affected by anaphylaxis who currently rely on carrying Epinephrine.
Nasus Pharma (NYSE:NSRX), a clinical-stage pharmaceutical company specializing in intranasal emergency medical treatments, has successfully completed its Initial Public Offering (IPO). The company raised $10 million in gross proceeds through the offering of 1,250,000 ordinary shares at $8.00 per share.
Trading commenced on the NYSE American exchange on August 13, 2025, under ticker NSRX. The underwriters have a 45-day option to purchase up to 187,500 additional shares. Proceeds will fund the development of their intranasal Epinephrine program, including manufacturing scale-up and Phase 2 studies, along with general corporate purposes.
Nasus Pharma (NYSE:NSRX), a clinical-stage pharmaceutical company specializing in intranasal emergency medical treatments, has announced the pricing of its Initial Public Offering (IPO). The company is offering 1,250,000 ordinary shares at $8.00 per share, aiming to raise $10 million in gross proceeds.
The company has granted underwriters a 45-day option to purchase up to 187,500 additional shares. Trading will commence on NYSE American LLC on August 13, 2025, under the symbol "NSRX". The proceeds will primarily fund the development of their intranasal Epinephrine program, including manufacturing scale-up and Phase 2 studies.
FAQ
What is the current stock price of Nasus Pharma Ltd. (NSRX)?
What is the market cap of Nasus Pharma Ltd. (NSRX)?
